

# STEP THERAPY CRITERIA

**BRAND NAME**

(generic)

**TREXIMET**  
**(sumatriptan/naproxen)**

**Status: CVS Caremark® Criteria**

**Type: Initial Step Therapy; Post Step Therapy Prior Authorization**

## POLICY

### FDA-APPROVED INDICATIONS

Treximet is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.

### Limitations of Use:

Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with Treximet, reconsider the diagnosis of migraine before Treximet is administered to treat any subsequent attacks.

Treximet is not indicated for the prevention of migraine attacks.

Safety and effectiveness of Treximet have not been established for cluster headache.

### INITIAL STEP THERAPY\*

*\*Include Rx and OTC products unless otherwise stated.*

If the patient has filled a prescription for at least a 30-day supply of generic sumatriptan AND generic naproxen within the past 120 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of migraine headache
- AND**
- The patient has tried and experienced an inadequate treatment response or intolerance to THREE triptan 5-HT<sub>1</sub> agonists
- AND**
- The patient has tried sumatriptan taken with naproxen as separate agents

Duration of Approval (DOA):

- 3020-D: DOA: 12 months

### REFERENCES

1. Treximet [package insert]. Morristown, NJ: Pernix Therapeutics, LLC; October 2021.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed April 27, 2023.

Treximet ST, Post PA Policy 3020-D UDR 06-2023

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/27/2023).
4. American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache* 2021;61:1021-1093.
5. Oskoui M, Pringsheim T, Holler-Managen Y, et al. Practice guideline update: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2019;93:487-499.

Treximet ST, Post PA Policy 3020-D UDR 06-2023

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.